Newamsterdam Pharma Stock Market Value
| NAMS Stock | 17.88 0.35 2.00% |
| Symbol | NewAmsterdam |
NewAmsterdam Pharma Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NewAmsterdam Pharma. If investors know NewAmsterdam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NewAmsterdam Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.21) | Revenue Per Share | Quarterly Revenue Growth 8.898 | Return On Assets | Return On Equity |
The market value of NewAmsterdam Pharma is measured differently than its book value, which is the value of NewAmsterdam that is recorded on the company's balance sheet. Investors also form their own opinion of NewAmsterdam Pharma's value that differs from its market value or its book value, called intrinsic value, which is NewAmsterdam Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NewAmsterdam Pharma's market value can be influenced by many factors that don't directly affect NewAmsterdam Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NewAmsterdam Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if NewAmsterdam Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NewAmsterdam Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
NewAmsterdam Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to NewAmsterdam Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of NewAmsterdam Pharma.
| 06/01/2024 |
| 02/26/2025 |
If you would invest 0.00 in NewAmsterdam Pharma on June 1, 2024 and sell it all today you would earn a total of 0.00 from holding NewAmsterdam Pharma or generate 0.0% return on investment in NewAmsterdam Pharma over 270 days. NewAmsterdam Pharma is related to or competes with Monte Rosa, Inventiva, Cullinan Oncology, Compass Therapeutics, Replimune, Crinetics Pharmaceuticals, and PureTech Health. NewAmsterdam Pharma is entity of United States More
NewAmsterdam Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure NewAmsterdam Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess NewAmsterdam Pharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 47.02 | |||
| Value At Risk | (5.13) | |||
| Potential Upside | 4.21 |
NewAmsterdam Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for NewAmsterdam Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as NewAmsterdam Pharma's standard deviation. In reality, there are many statistical measures that can use NewAmsterdam Pharma historical prices to predict the future NewAmsterdam Pharma's volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.33) | |||
| Total Risk Alpha | (0.38) | |||
| Treynor Ratio | 0.3753 |
NewAmsterdam Pharma Backtested Returns
NewAmsterdam Pharma has Sharpe Ratio of close to zero, which conveys that the firm had a close to zero % return per unit of risk over the last 3 months. NewAmsterdam Pharma exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify NewAmsterdam Pharma's Risk Adjusted Performance of (0.03), standard deviation of 6.11, and Mean Deviation of 2.79 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of -0.9, which conveys possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning NewAmsterdam Pharma are expected to decrease slowly. On the other hand, during market turmoil, NewAmsterdam Pharma is expected to outperform it slightly. At this point, NewAmsterdam Pharma has a negative expected return of -0.0266%. Please make sure to verify NewAmsterdam Pharma's value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if NewAmsterdam Pharma performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.29 |
Weak reverse predictability
NewAmsterdam Pharma has weak reverse predictability. Overlapping area represents the amount of predictability between NewAmsterdam Pharma time series from 1st of June 2024 to 14th of October 2024 and 14th of October 2024 to 26th of February 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of NewAmsterdam Pharma price movement. The serial correlation of -0.29 indicates that nearly 29.0% of current NewAmsterdam Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.29 | |
| Spearman Rank Test | -0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 8.21 |
NewAmsterdam Pharma lagged returns against current returns
Autocorrelation, which is NewAmsterdam Pharma stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting NewAmsterdam Pharma's stock expected returns. We can calculate the autocorrelation of NewAmsterdam Pharma returns to help us make a trade decision. For example, suppose you find that NewAmsterdam Pharma has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
NewAmsterdam Pharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If NewAmsterdam Pharma stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if NewAmsterdam Pharma stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in NewAmsterdam Pharma stock over time.
Current vs Lagged Prices |
| Timeline |
NewAmsterdam Pharma Lagged Returns
When evaluating NewAmsterdam Pharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of NewAmsterdam Pharma stock have on its future price. NewAmsterdam Pharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, NewAmsterdam Pharma autocorrelation shows the relationship between NewAmsterdam Pharma stock current value and its past values and can show if there is a momentum factor associated with investing in NewAmsterdam Pharma.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.